Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rivaroxaban for symptomatic isolated distal deep vein thrombosis
NCT02722447Phase 3Unknown
- Start
- Jan 2017
- Primary completion
- Jun 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of rivaroxaban in deep vein thrombosis (DVT). Primary endpoint: Recurrent Venous Thromboembolism at 24 months. Status: unknown.
02
Drugs
rivaroxaban
03
Conditions
deep vein thrombosis (DVT)
Beyond the preview
Go deeper on NCT02722447.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02722447.